T
Teh Ying Chou
Researcher at Taipei Veterans General Hospital
Publications - 173
Citations - 5895
Teh Ying Chou is an academic researcher from Taipei Veterans General Hospital. The author has contributed to research in topics: Lung cancer & Adenocarcinoma. The author has an hindex of 35, co-authored 149 publications receiving 4390 citations. Previous affiliations of Teh Ying Chou include National Yang-Ming University & National Chiao Tung University.
Papers
More filters
Journal ArticleDOI
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Ming-Sound Tsao,Keith M. Kerr,Mark M. Kockx,Mary Beth Beasley,Alain C. Borczuk,Johan Botling,Lukas Bubendorf,Lucian R. Chirieac,Gang Chen,Teh Ying Chou,Jin Haeng Chung,Sanja Dacic,Sylvie Lantuejoul,Mari Mino-Kenudson,Andre L. Moreira,Andrew G. Nicholson,Masayuki Noguchi,Giuseppe Pelosi,Claudia Poleri,Prudence A. Russell,Jennifer L. Sauter,Erik Thunnissen,Ignacio I. Wistuba,Hui Yu,Murry W. Wynes,Melania Pintilie,Yasushi Yatabe,Fred R. Hirsch +27 more
TL;DR: The Blueprint (BP) Programmed Death Ligand 1 (PD-L1) Immunohistochemistry Comparability Project is a pivotal academic/professional society and industrial collaboration to assess the feasibility of harmonizing the clinical use of five independently developed commercial PD-L 1 immunohistochemical assays.
Journal ArticleDOI
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer
Teh Ying Chou,Chao-Hua Chiu,Ling-Hui Li,Chun-Yen Hsiao,Chin-Yuan Tzen,Kuo-Ting Chang,Yuh Min Chen,Reury-Perng Perng,Shih-Feng Tsai,Chun-Ming Tsai +9 more
TL;DR: Analysis of EG FR tyrosine kinase mutations in lung adenocarcinoma is of clinical significance, as it can permit the customization of treatment with EGFR tyrosin kinase inhibitors.
Journal ArticleDOI
Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival
Jung Jyh Hung,Yi Chen Yeh,Wen Juei Jeng,Wen Juei Jeng,Kou-Juey Wu,Biing Shiun Huang,Yu Chung Wu,Teh Ying Chou,Wen Hu Hsu +8 more
TL;DR: In lung adenocarcinoma, the IASLC/ATS/ERS classification system has significant prognostic and predictive value regarding death and recurrence.
Journal ArticleDOI
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer
Yasushi Yatabe,Sanja Dacic,Alain C. Borczuk,Arne Warth,Prudence A. Russell,Sylvie Lantuejoul,Mary Beth Beasley,Erik Thunnissen,Giuseppe Pelosi,Natasha Rekhtman,Lukas Bubendorf,Mari Mino-Kenudson,Akihiko Yoshida,Kim R. Geisinger,Masayuki Noguchi,Lucian R. Chirieac,Johan Bolting,Jin Haeng Chung,Teh Ying Chou,Gang Chen,Claudia Poleri,Fernando López-Ríos,Mauro Papotti,Lynette M. Sholl,Anja C. Roden,William D. Travis,Fred R. Hirsch,Keith M. Kerr,Ming-Sound Tsao,Andrew G. Nicholson,Ignacio I. Wistuba,Andre L. Moreira +31 more
TL;DR: The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors.
Journal ArticleDOI
PD-L1 Testing for Lung Cancer in 2019 : Perspective From the IASLC Pathology Committee
Sylvie Lantuejoul,Ming Sound-Tsao,Wendy A Cooper,Nicolas Girard,Fred R. Hirsch,Anja C. Roden,Fernando López-Ríos,Deepali Jain,Teh Ying Chou,Noriko Motoi,Keith M. Kerr,Yasushi Yatabe,Elisabeth Brambilla,John W. Longshore,Mauro Papotti,Lynette M. Sholl,Erik Thunnissen,Natasha Rekhtman,Alain C. Borczuk,Lukas Bubendorf,Yuko Minami,Mary Beth Beasley,Johan Botling,Gang Chen,Jin Haeng Chung,Sanja Dacic,David M. Hwang,Dongmei Lin,Andre L. Moreira,Andrew G. Nicholson,Masayuki Noguchi,Giuseppe Pelosi,Claudia Poleri,William D. Travis,Akihiko Yoshida,Jillian B. Daigneault,Ignacio I. Wistuba,Mari Mino-Kenudson +37 more
TL;DR: Although PD-L1 IHC test is now deployed in the most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging due to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided.